Submitted on February 3, 2009
Accepted on October 23, 2009
Posttranscriptional Regulation of Plasminogen Activator Inhibitor-1 Expression in Human Pleural Mesothelial Cells
Sreerama Shetty1*, Thirunavukkarasu Velusamy1, Rashmi S Shetty1, Amarnath Satheesh Marudamuthu1, Shwetha K Shetty1, Galina Florova1, Torry Tucker1, Kathy Koenig1, Praveenkumar Shetty1, Yashodhar P Bhandary1, and Steven Idell1
1 The Texas Lung Injury Institute, The University of Texas Health Center at Tyler, Tyler, Texas, United States
* To whom correspondence should be addressed. E-mail: sreerama.shetty{at}uthct.edu.
The plasminogen activator inhibitor (PAI-1) effectively blocks the activities of both free and receptor bound urokinase-type plasminogen activator (uPA). Incubation of cultured human pleural mesothelial (Met5A) cells with TGF-
increased PAI-1 protein. TGF-
-globin mRNA, indicating that the binding sequence accelerates decay of endogenous PAI-1 mRNA. Competitive inhibition by overexpression of the 33 nt binding sequence in MeT5A cells reduced PAI-1 mRNA decay and increased PAI-1 protein and mRNA expression, indicating that the PAI-1 mRNABp destabilizes PAI-1 mRNA by its interaction with the endogenous 33 nt binding sequence. Incubation of Met5A cells with TGF-
attenuated the interaction of the PAI-1 mRNABp with the 33 nt sequence. By conventional and affinity purification, we isolated the PAI-1 mRNABp and confirmed its identity as 6-Phospho-D-Gluconate-NADP oxidoreductase (6-PGD). 6-PGD specifically interacts with the full length as well as the 33 nt sequence of the PAI-1 mRNA 3'UTR. This newly recognized pathway could influence expression of PAI-1 by mesothelial or mesothelioma cells at the level of mRNA stability in the context of pleural inflammation or malignancy.
Key words: pleural
mesothelial cells
plasminogen activator
Fibrinolysis